Faron Pharmaceuticals Oy (LON:FARN)
41.40p-0.24%
Spriggl Score: Poor— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Promising trial data boosts hope but binary risk and heavy dilution threaten total loss.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immuno…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £84.0M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Faron Pharmaceuticals Oy and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free